Factor Xa inactivation in acute coronary syndrome

Current Pharmaceutical Design

Volumn 14, Issue 12, 2008, Pages 1186-1190

  Barantke, Melanie ^a   Bonnemeier, Hendrik ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYSACCHARIDE;

ACUTE CORONARY SYNDROME; ANTIBODY PRODUCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART INFARCTION; HEART REINFARCTION; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; INJECTION SITE REACTION; INTRAOCULAR HEMORRHAGE; LUNG EMBOLISM; MORBIDITY; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SURGICAL MORTALITY; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VISUAL IMPAIRMENT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; POLYSACCHARIDES;

EID: 47149105081     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784246117     Document Type: Review

References (25)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6): e85-151 [Erratum in: Eirculation 2006; 113(14): e696, Circulation 2006; 114(23): E630].
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40(7): 1366-74.
3. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J 2007; 28: 2077-86.
4. Mahaffey KW, Ferguson JJ. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: The SYNERGY trial. Am Heart J 2005; 149(4 Suppl): S81-90.
5. The Matisse investigators. Subcutaneous fordaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702 [Erratum in N Engl J Med 2004; 350: 423].
6. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Matisse Investigators, Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 2004; 140(11): 867-73.
7. The OASIS-5 Investigators. Comparison of fondaparinux compared to enoxaparin in acute coronary syndromes without ST segment elevation. N Engl J Med 2006; 354(14): 1464-76.
8. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtra tion. Thromb Res 1976; 9(6): 575-83.
9. Johnson EA, Mulloy B. The molecular weight range of mucosal heparin preparations. Carbohydr Res 197; 51: 119-27.
10. Harenberg J. Pharmacology of low molecular weight heparin. Sem Thromb Hemost 1990; 16: 12-8.
11. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218-22.
12. Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, et al. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 1981; 197(3): 599-609.
13. Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 688-98.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
15. Boneu B, Necciari J, Cariou R, Sie P, Gabaig AM, Kieffer G, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ Org31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74(6): 1468-73.
16. Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41(Suppl 2): 1-9.
17. Paolucci F, Clavies MC, Donat F, Necciari J. Fondaparinux sodium mechanism of action: Identification of specific binding to purified and human plasm-derived proteins. Clin Pharmacokinet 2002; 41 (Suppl 2): 11-8.
18. Greinacher A. Antigen generation in heparin-associated thrombo-cytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Sem Thromb Haemost 1995; 21: 106-16.
19. Amiral J, Lormeau JC, Marfaing-Koka A. Vissac AM, Wolf M, Boyer-Neumann C, et al. Absence of cross-reacivity of SR91107A/ORG31540 pentasaccharide with antibodies to hepatin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-7.
20. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-44.
21. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40(7): 1366-74.
22. Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 2249-55.
23. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 2004; 292(1): 45-54.
24. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006; 295(13): 1519-30.
25. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non - ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: E148-304.